ClinicalTrials.gg
RecruitingNCT07846722Updated Sep 29, 2026

Esmolol Versus Dexmedetomidine for Opioid-sparing in Laparoscopic Gynecological Surgery

An interventional study of Esmolol hydrochloride and Dexmedetomidine in Pain, Acute Post-Operative, Dexmedetomidine and Analgesia, sponsored by Vasiliki Samartzi. Recruiting at 1 site in Greece. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Vasiliki Samartzi · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 136 studies testing dexmedetomidine in Pain, Postoperative — 35 open to participants now, 38 under way, 5 of them phase 3. Dexmedetomidine · Pain, Postoperative.

Planned enrollment
51st of 136
90 · median 85
Started
2026
with 18 others
No phase
47 of 136
13 open now
Primary completion
2026-12
later than 17 of 37 live
Registered
123rd of 136
by date

Among the 136 studies testing dexmedetomidine in Pain, Postoperative, this one is the 51st largest by planned enrollment, is one of 19 that started in 2026, is one of 47 with no phase, reaches primary completion later than 17 of the 37 other live ones, and was the 123rd registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

35 of the 136 studies testing dexmedetomidine in Pain, Postoperative are open now, in 9 countries. Recruiting first, the newest first:

29 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 20 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing dexmedetomidine in Pain, Postoperative, or all of them as a file.
02

Study summary

The aim of this study is to investigate and compare the effects of a continuous infusion of low-dose esmolol and dexmedetomidine versus placebo on intraoperative and postoperative opioid consumption and analgesic efficacy in patients undergoing laparoscopic hysterectomy.

Read the detailed description

Postoperative pain remains one of the most common problems in modern anesthesiological practice, even in minimally invasive surgical techniques, such as laparoscopic gynecological procedures. Despite the use of various analgesic regimens, the need for opioids remains significant, resulting in adverse effects such as nausea, vomiting, sedation, and delayed recovery. In recent years, the focus has shifted toward opioid-sparing strategies through the use of adjunctive medications during anesthesia. Among these, esmolol and dexmedetomidine are drugs that have been studied as adjuncts for reducing intraoperative and postoperative opioid requirements.

Although the literature supports the opioid-sparing effects of both agents, data directly comparing esmolol and dexmedetomidine in the context of standardized total intravenous anesthesia (TIVA) and postoperative analgesia via PCA in laparoscopic gynecological surgeries remain limited. Furthermore, it is unclear whether esmolol can offer a benefit similar to that of dexmedetomidine, with a potentially more favorable recovery profile. Therefore, this randomized, double-blind, placebo-controlled study with three parallel groups was designed to compare the effects of intraoperative esmolol and dexmedetomidine infusions versus placebo on opioid consumption and quality of recovery.

03

Conditions studied

  • Pain, Acute Post-Operative
  • Dexmedetomidine
  • Analgesia
  • Esmolol
  • Nociceptive Pain
  • Laparoscopic Hysterectomy
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients
  • (ASA) classification I-II
  • Laparoscopic hysterectomy

Exclusion criteria

Exclusion Criteria:

  • (BMI) >35 kg/m2
  • β-blocker administration preoperatively
  • systematic use of analgesic agents preoperatively
  • chronic pain syndromes preoperatively
  • neurological or psychiatric disease on treatment
  • pregnancy
  • severe hepatic or renal disease
  • history of cardiovascular diseases/ arrhythmias/ conduction abnormalities
  • hemodynamic instability
  • patients with a known or undergoing surgery for oncological reasons
  • known allergy to a local anesthetic
  • drug or alcohol abuse
  • language or communication barriers
  • lack of
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Group A - Esmolol Hydrochloride

    Loading dose of esmolol 0.05 mL/kg (10 mg/mL) and maintenance dose of esmolol 0.3 mL/kg/h (10 mg/mL).

    Drug: Esmolol hydrochloride

  • Active comparator
    Group B - Dexmedetomidine

    Loading dose of dexmedetomidine 0.05 mL/kg (4 mcg/ml) and maintenance dose of dexmedetomidine 0.3 mL/kg/h (1.67 mcg/ml).

    Drug: Dexmedetomidine

  • Placebo comparator
    Group C - Placebo

    Loading dose of 0.9% sodium chloride 0.05 mL/kg and maintenance dose of 0.9% sodium chloride 0.3 mL/kg/h.

    Drug: Normal (0.9%) saline

Interventions

  • In the esmolol group, patients will receive a loading dose of esmolol administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative esmolol infusion.

  • In the dexmedetomidine group, patients will receive a loading dose of dexmedetomidine administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative dexmedetomidine infusion.

  • DrugNormal (0.9%) saline

    In the placebo group, patients will receive a loading dose of normal saline administered over 10 minutes in 100 mL of normal saline, followed by a continuous intraoperative normal saline infusion.

06

What researchers measure

Primary outcomes

  1. Total postoperative opioid consumption

    Total morphine consumption administered via patient-controlled analgesia (PCA), expressed in milligrams (mg).

    Time frame: First 24 hours postoperatively

  2. PCA utilization parameters

    Number of PCA attempts and number of successful PCA deliveries as indicators of analgesic demand and utilization efficiency.

    Time frame: First 24 hours postoperatively

Secondary outcomes

  1. Postoperative pain intensity

    Pain intensity will be assessed using the Numerical Rating Scale (NRS) at rest and during coughing ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable". Measurements will be recorded in the Post-Anesthesia Care Unit (PACU) at arrival and discharge, and at 6, 12, and 24 hours postoperatively.

    Time frame: PACU arrival and discharge (1 hour), & 6, 12, and 24 hours postoperatively

  2. Time to first patient-controlled analgesia (PCA) activation

    Time elapsed from arrival in the PACU to the first demand for analgesia via the PCA device.

    Time frame: Up to 24 hours postoperatively

  3. Satisfaction from analgesia

    Satisfaction from postoperative analgesia on a four-point Likert scale with 1 marked as minimal satisfaction and 4 as maximal satisfaction

    Time frame: 6 hours postoperatively

  4. Time with adequate nociception control (NOL <25)

    Total duration during surgery in which the Nociception Level (NOL) index remains below 25.

    Time frame: Intraoperatively

  5. Intraoperative fentanyl consumption

    Dose of required fentanyl intraoperatively to maintain systolic arterial blood pressure and heart rate within the 20% of baseline value

    Time frame: Intraoperatively

  6. Incidence of bradycardia and hypotension and related treatment

    Incidence of intraoperative bradycardia and/or hypotension, as well as total doses of vasoactive agents used for their management.

    Time frame: Intraoperatively

  7. Total propofol consumption

    Total dose of propofol administered intraoperatively, expressed in mg/kg.

    Time frame: Intraoperatively

  8. Sedation level on arrival and discharge from PACU

    Sedation will be assessed with a 5-point sedation scale, where: 1, patient perfectly conscious; 2, patient feels a little drowsy; 3, patient seems to be sleeping but immediately reacts to verbal stimulation; 4, patient seems to be sleeping but slowly reacts to verbal stimulation and 5, patient seems to be sleeping and does not react to verbal stimulation but does react to a stimulus such as shaking or pain

    Time frame: PACU admission and discharge (1 hour)

  9. Length of stay in the Post-Anesthesia Care Unit (PACU)

    Time spent in the PACU, with discharge criteria defined as White-Song score ≥12 and NRS \<4. Numeric Rating Scale (NRS) ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable". The White-Song score assesses 7 clinical parameters, each scored from 0 to 2, for a maximum total of 14 points: Consciousness, Physical Activity, Hemodynamic Stability, Respiratory Stability, Oxygen Saturation, Postoperative Pain, Postoperative Nausea and Vomiting (PONV).

    Time frame: Until PACU discharge (1 hour)

  10. Incidence of postoperative nausea and vomiting

    Occurrence of nausea and/or vomiting during the postoperative period.

    Time frame: Up to 24 hours postoperatively

  11. Change from baseline in Quality of Recovery (QoR)-15 score after surgery

    The QoR-15 is a quality of recovery scale that consists of 15 questions (items),including questions regarding pain (2 items), physical comfort (5 items), self-care ability (2 items), psychological support (2 items) and emotional state (4 items). Every item is scored on a scale of 10, with the lowest total score of 0 and the highest score of 150. The higher the score, the better the recovery quality of the patient

    Time frame: 24 hours postoperatively

  12. Total hospital length of stay

    Total duration of hospitalization from surgery to discharge, expressed in days.

    Time frame: From surgery until hospital discharge (4 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Watts R, Thiruvenkatarajan V, Calvert M, Newcombe G, van Wijk RM. The effect of perioperative esmolol on early postoperative pain: A systematic review and meta-analysis. J Anaesthesiol Clin Pharmacol. 2017 Jan-Mar;33(1):28-39. doi: 10.4103/0970-9185.202182. PubMed 28413270 ↗
  • Sun Y, Yao Y, Li Y, Deng W. Dexmedetomidine for opioid-sparing postoperative analgesia: a systematic review and meta-analysis. BMC Anesthesiol. 2026 Jan 13;26(1):103. doi: 10.1186/s12871-025-03606-w. PubMed 41527017 ↗
  • Neto EDDS, de Lara FST, Abreu SN, Sanches MC, de Freitas MCF, Oliveira ARDS, Nogueira CS, Carvalho VH. Esmolol as an Adjunct in Multimodal Anesthesia: A Systematic Review and Meta-Analysis of Its Opioid-Sparing and Analgesic Effects. Anesth Analg. 2026 May 1;142(5):882-897. doi: 10.1213/ANE.0000000000007787. Epub 2025 Oct 24. PubMed 41134986 ↗
  • Gelineau AM, King MR, Ladha KS, Burns SM, Houle T, Anderson TA. Intraoperative Esmolol as an Adjunct for Perioperative Opioid and Postoperative Pain Reduction: A Systematic Review, Meta-analysis, and Meta-regression. Anesth Analg. 2018 Mar;126(3):1035-1049. doi: 10.1213/ANE.0000000000002469. PubMed 29028742 ↗
  • Salome A, Harkouk H, Fletcher D, Martinez V. Opioid-Free Anesthesia Benefit-Risk Balance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2021 May 12;10(10):2069. doi: 10.3390/jcm10102069. PubMed 34065937 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 4 months after the start.

Of 2,097 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 2,110 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2026
First posted
Sep 29, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Feb 1, 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846722
Lead sponsor
Vasiliki Samartzi
Responsible party
Vasiliki Samartzi (Anesthesiologist, Principal Investigator, National and Kapodistrian University of Athens) — Sponsor-investigator
First posted
Sep 29, 2026
Start date
Jul 15, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Feb 1, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Vasiliki Samartzi
Contact
v.samartzi2@gmail.com
+30 6939001517
Kassiani Theodoraki, PhD, DESA
Contact
ktheodoraki@hotmail.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Esmolol · Dexmedetomidine

Start the discussion